bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract A84: Evidence of social influence promoting cancer knowledge and intent to obtain mammography among rural Latinas.
Authors: Ceballos Rachel , Molina Yamile , Thompson Beti 
Published: August 2014

Abstract
Background: Latinas are much less likely to undergo mammography and remain adherent to mammography guidelines. Recent research has begun to identify factors which may enable screening behavior and promote cancer knowledge in underserved Latina populations. These factors include access to care, personal history of mammography, and socio-demographic characteristics. Given the Latino traditions of respecto (respect/deference to authority) and familismo (importance of immediate and extended family), recommendations by physicians, family, or friends may also be integral to mammography screening practices and cancer knowledge. However, this relationship has not been widely examined. The goal of this study is to evaluate the role of physician and family recommendation on intent for mammography screening and cancer knowledge among Latinas living in a rural community.
Methods: This study utilized baseline data collected as part of a larger cancer education project. Participants were Hispanic women between the ages of 40-79 living in a rural agricultural community of Washington State. Data were collected by bilingual and bicultural community residents with extensive training as promotoras. Logistic regression analyses were conducted to identify significant determinants of mammography screening and cancer knowledge.
Results: Our sample included 79 rural Latina women aged 40-74 (M = 49.85, SD = 8.83). The importance socio-demographic, access to care, and previous mammography history factors were included as covariates, a history of family recommendations to obtain a mammogram were associated with greater cancer knowledge. A history of physician recommendations to obtain a mammogram was associated with plans to obtain a mammogram, after adjusting for covariates noted above.
Conclusion: Our study highlights the importance of social factors for cancer knowledge and mammography use in Latina populations, especially with regard to discussions and recommendations with physicians and family concerning mammograms. Future interventions should incorporate recommendations from a variety of social sources to promote mammography screening among Latina women.
Citation Format: Rachel Ceballos, Yamile Molina, Beti Thompson. Evidence of social influence promoting cancer knowledge and intent to obtain mammography among rural Latinas. [abstract]. In: Proceedings of the Fifth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2012 Oct 27-30; San Diego, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2012;21(10 Suppl):Abstract nr A84.
Abstract B07: GMaP/BMaP Region VI: Utilizing a community-based participatory research approach to deliver culturally appropriate colorectal cancer education.
Authors: Harbach Heidi M. , Thompson Beti 
Published: August 2014

Abstract
Background: Colorectal cancer is a leading cause of cancer incidence and mortality with well-documented disparities among various racial/ethnic groups. Early detection of colorectal cancer is key, yet less than half of the US population aged 50+ is current on recommended testing. As a GMaP/BMaP partnership, the Fred Hutchinson Cancer Research Center and San Diego State University are working to build relationships with community-based organizations across Region VI (Alaska, Washington, Oregon, California, Hawaii, Guam, and American Samoa) to address this disparity.
Methods: GMaP/BMaP issued a request for proposals throughout Region VI. Proposed projects were received from all but one state/territory in the region, and six projects were funded. Projects proposed to conduct community-based participatory research (CBPR) activities and are addressing colorectal cancer awareness, education, prevention, and screening among underrepresented populations including: Iraqi refugees, Hispanics, Alaska Natives, Filipinos, and African Americans. All projects will be tailored to be culturally and linguistically appropriate for each population.
Results: Based on a regional needs assessment, a key finding is that community/academic partnerships are needed to launch activities to educate communities about colorectal cancer. The funded projects are currently in the field.
Conclusion: Our hypothesis is that CBPR is a needed mechanism for increasing knowledge of colorectal cancer prevention and screening in a culturally appropriate way. As a result of using a CBPR model, partnerships between community organizations and academic institutions will develop into sustainable, reciprocal relationships. The development of these relationships is a critical component in the success of the pilot program.
Citation Format: Heidi M. Harbach, Beti Thompson. GMaP/BMaP Region VI: Utilizing a community-based participatory research approach to deliver culturally appropriate colorectal cancer education. [abstract]. In: Proceedings of the Fifth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2012 Oct 27-30; San Diego, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2012;21(10 Suppl):Abstract nr B07.
Abstract B34: Pregnancy-associated breast cancer and differentially expressed microRNAs.
Authors: Munoz-Rodriguez Jose Luis , Vrba Lukas , Thompson-Carino Patricia A. , Martinez Maria Elena , Futscher Bernard W. 
Published: August 2014

Abstract
MicroRNAs (miRNAs) are short-stranded, non-coding RNAs that regulate gene expression. The expression of miRNAs is often deregulated in breast cancer. Epigenetic modifications, such as DNA methylation, have been shown to regulate miRNA gene expression in breast cancer. In our study, we set out to analyze the role that differentially expressed miRNAs play in pregnancy associated breast cancer (PABC) amongst a Hispanic population within the Ella Binational Breast Cancer study. PABC is defined as cancer that arises within a time-frame of 10 years after pregnancy. Previous studies have shown that women diagnosed with PABC do far worse than women diagnosed with non-PABC. Our hypothesis is that the epigenetic regulation of miRNA genes contributes to poor survival in PABC. We are testing our hypothesis using a cohort of post-partum formalin fixed, paraffin embedded (FFPE) breast cancer tissues from a Hispanic population. Using Exiqon miRCURY LNA™ Universal RT microRNA PCR panels we were able to test for the expression of 360 human miRNAs, which our laboratory previously identified as miRNAs that are specific for human mammary cells. Preliminary data from a small subset of samples showed six miRNAs that were differentially expressed (having &gt; 4-fold expression and a p-value ≤ 0.05) between PABC and non-PABC (hsa-miR-876-5p; hsa-miR-299-3p; hsa-miR-137; hsa-miR-187; hsa-miR-873; hsa-miR-190b ). Several of these miRNAs have been implicated in carcinogenesis. Our goals are to identify differentially expressed miRNAs and to determine the extent of the epigenetic regulation of those miRNAs. These miRNAs will be evaluated for their potential utility as targets of epigenetic regulation and targets for therapeutic interventions. In addition, our studies will be the first to look at epigenetic mechanisms related to PABC in Hispanics. Hispanics have one of the highest fertility rates and an early breast cancer diagnosis. Therefore, our results will elucidate factors associated with this PABC disparity.
Citation Format: Jose Luis Munoz-Rodriguez, Lukas Vrba, Patricia A. Thompson-Carino, Maria Elena Martinez, Bernard W. Futscher. Pregnancy-associated breast cancer and differentially expressed microRNAs. [abstract]. In: Proceedings of the Fifth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2012 Oct 27-30; San Diego, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2012;21(10 Suppl):Abstract nr B34.
Abstract B63: Receptor status in early-onset breast cancer across races.
Authors: Singh Mandeep , Ding Yi , Zhang Liying , Lee Susan , Song Dong , Grover Shruti , Doval Dinesh Chandra , Ross Dara S. , Shao Charles , Zhu Changcheng , Xu Ruliang , He Zili , Zhang David , Wang Jinhua , Chang Victor , Chen Margaret , August Phyllis , Lee Peng 
Published: August 2014

Abstract
Breast cancer is a heterogeneous disease and, racial disparity of breast cancer has been known to influence the age of occurrence, prognosis and response to the treatment. The objective of this study is to analyze the variations in the expression of the receptor proteins- estrogen receptor (ER), progesterone receptor (PR) and HER-2/neu, in early onset breast cancer cross races. Data was collected by reviewing patient charts obtained from the participating institutions and was stratified according to age (Younger group: 40 year old and younger women; older age group: greater than 40 year old women), races (Caucasian, African American, Hispanic, Chinese and Indian), receptor status (ER, PR and HER-2) according to Luminal A, B, HER-2 and Triple Negative Breast Cancer (TNBC) subtypes, grade and stage. Results show that while African American women have higher percentage of TNBC than the Caucasian, there are evident variations in receptor status among other races. In Chinese woman of younger age group, 18.2% presented with TNBC subtype. However, in the same group, the HER-2 overexpression (ER-/PR-, HER-2+), luminal A (ER+/PR+, HER2-) and B (ER+/PR+, HER2+) subtypes were 9.1%, 45.5% and 9.0% respectively. In Indian women, TNBC has been found to be about 1.5 folds higher in younger age group (34 %) than older group (23 %) while HER-2 overexpression and the luminal A and B subgroups were 14.3%, 42.2% and 9.5%, respectively, somewhat similar to those in Chinese women. Our preliminary findings demonstrated that the expression of receptor proteins (ER, PR and Her-2/neu) in early onset breast cancer differs among different ethnic or racial women, suggesting a biological basis of distinct prognosis or therapeutic response related to racial disparities. This study will help to develop optimal personalized management strategies for breast cancer cross the races.
Citation Format: Mandeep Singh,, Yi Ding, Liying Zhang, Susan Lee, Dong Song, Shruti Grover, Dinesh Chandra Doval, Dara S. Ross, Charles Shao, Changcheng Zhu, Ruliang Xu, Zili He, David Zhang, Jinhua Wang, Victor Chang, Margaret Chen, Phyllis August, Peng Lee,,. Receptor status in early-onset breast cancer across races. [abstract]. In: Proceedings of the Fifth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2012 Oct 27-30; San Diego, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2012;21(10 Suppl):Abstract nr B63.
Abstract B87: Factors associated with mammography screening in cities of four contiguous U.S. states whose 2010 mammography rates for women aged 40 and older ranged from 63.8 to 75.2 percent.
Authors: Han Ann M. , Sequeira Shwetha , Berger Loretta 
Published: August 2014

Abstract
Objectives: To evaluate access to care, socio-economic status (SES), and other demographic factors at regional and individual levels that predict the probability of women 40 and older getting mammography screening for breast cancer within the previous two years in cities of Idaho, which has the lowest mammography rates nationally, and contiguous states of Washington, Montana and North Dakota.
Methods: We conducted a cross-sectional analysis of 2010 Center for Disease Control (CDC) Behavioral Risk Factor Surveillance System (BRFSS) individual survey data for women 40 and over residing in cities of Idaho, Washington, Montana, and North Dakota. Regional characteristics for cities within each state included a created variable of the sum of general and OB/GYN physicians divided by the civil population to represent provider density and 2010 American Community Survey demographic data from the US census spatially linked to the study area using ArcGIS.
Results: Having a personal doctor was significantly associated with having a mammogram within the previous two years for women 40 and older in all but one city. Controlling for socio-demographic variables, women 40 and older who had a routine check-up within last 2 years had greater odds of having timely mammography for all cities. The provider density was significantly associated with mammography in the previous two years only in cities in Idaho, which had the lowest mammography rates nationally. Women 40 and older in cities with higher SES (income &gt;50K, high school education or greater) had greater odds of having a mammogram within the previous two years in cities of Idaho, N. Dakota and Washington, but not Montana.
Conclusions: State-wide policies directed at improving mammography should include an effort to establish a relationship with a medical care provider.
Citation Format: Ann M. Han, Shwetha Sequeira, Loretta Berger. Factors associated with mammography screening in cities of four contiguous U.S. states whose 2010 mammography rates for women aged 40 and older ranged from 63.8 to 75.2 percent. [abstract]. In: Proceedings of the Fifth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2012 Oct 27-30; San Diego, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2012;21(10 Suppl):Abstract nr B87.
Abstract B93: Resuscitating cancer immunosurveillance by combining Notch 1 and death receptor-activating therapy.
Authors: Dudimah Duafalia F. , Uzhachenko Roman V. , Pellom Samuel T. , Biktasova Asel K. , Dikov Mikhail M. , Carbone David P. , Shanker Anil 
Published: August 2014

Abstract
Notch signaling plays diverse roles in lymphocyte differentiation and tumor angiogenesis. Our recent findings implicate the role of the Notch 1 pathway in promoting antitumor immune effector functions. We explored the effects of Notch 1 stimulation on T cell immunity and its potential pharmacological activation using multivalent Delta-like Notch 1 ligand DLL1 cluster in combination with the proteasome inhibitor bortezomib, which could stabilize Notch 1 activation. Bortezomib was found to selectively sensitize solid tumor cells to apoptosis by upregulating death receptors on tumor cells and amplifying caspase-8 activation in the death-inducing signaling complex. This resulted in reduced pulmonary nodules of injected tumor cells in mice. Additionally, in an in vivo tumor setting, no adverse effects of bortezomib were observed on the antigen-specific T cell proliferative or cytolytic functions. But no long-term survival benefits could be obtained, possibly due to the immunosuppressive effects of the tumor. In our more recent studies, we observed that DLL1-specific immune Notch activation could enhance antitumor T cell immunity by overcoming tumor-associated immunosuppression in D459 and Lewis lung carcinoma models. The results offer a novel combinatorial approach to abrogate the immunosuppressive circuitries operating in the tumor microenvironment with a potential to reduce tumor burden and resuscitate tumor-specific immunity. This work has important translational implications for improving immunotherapy in cancer patients, and may provide insights into new strategies for cancer prevention.
Citation Format: Duafalia F. Dudimah, Roman V. Uzhachenko, Samuel T. Pellom, Jr., Asel K. Biktasova, Mikhail M. Dikov, David P. Carbone, Anil Shanker. Resuscitating cancer immunosurveillance by combining Notch 1 and death receptor-activating therapy. [abstract]. In: Proceedings of the Fifth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2012 Oct 27-30; San Diego, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2012;21(10 Suppl):Abstract nr B93.
Abstract ED02-01: Overview on genetic ancestry and its use in cancer disparities research.
Authors: Kittles Rick A. 
Published: August 2014

Abstract
Given the current attention on health disparities and mounting findings showing genetic variants associated with heightened disease risk or a particular treatment response that differ significantly in frequency among ethnic groups, identifying the influence of genetic ancestry on complex phenotypes may allow for the de-construction of race in most study designs. Ancestry informative markers (AIMs) and the use of genetic ancestry have been instrumental in understanding disparate disease risk and poor health outcomes. Several statistical methods are currently used to infer population structure, individual genetic ancestry, and admixture mapping. Here we provide an overview on AIMs and the use of genetic ancestry in cancer disparities studies. Examples are provided which reveal that the study of genetic ancestry and health outcomes may strongly entail both biologic and sociological factors.
Citation Format: Rick A. Kittles. Overview on genetic ancestry and its use in cancer disparities research. [abstract]. In: Proceedings of the Fifth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2012 Oct 27-30; San Diego, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2012;21(10 Suppl):Abstract nr ED02-01.
Abstract ED03-05: Innovative technology development to advance biospecimen science.
Authors: Dickherber Anthony 
Published: August 2014

Abstract
In 1998, the National Cancer Institute (NCI) established the groundwork for a highly successful program focused on innovative technology development to overcome persistent barriers for cancer researchers and clinicians. Unlike other initiatives of the time, the Innovative Molecular Analysis Technologies (IMAT) Program solicited only the most cutting-edge ideas, thus restricting its application pool to those projects that had the potential to be truly transformative. By doing so, the program filled a void that no other program at the NCI or NIH filled at the time. In 2005, the IMAT program introduced an additional focus on supporting innovative technology development that uniquely advanced the field of biospecimen science. Technologies supported by this mechanism have seen a disproportionately high level of success. The IMAT program continues to represent a unique resource for highly innovative technology development, but runs alongside several active programs at the NCI for supporting cancer-relevant technologies.
The full reauthorization of the IMAT program in fall of 2011 by the NCI for 2012-2013 demonstrates a significant commitment, especially under ever tightening fiscal constraints, to supporting innovative technology development for cancer research and clinical care. The IMAT program utilizes unique funding mechanisms to better support investigators through both the early and advanced stages of technology development over traditional funding mechanisms for exploratory research. Moreover, receipt of an IMAT award offers membership to a truly unique community of investigators that meet annually to share progress and exchange ideas. A variety of IMAT-supported research projects will be highlighted to demonstrate the variety and level of innovation evident in the IMAT portfolio of supported research. Potential projects of interest and identified technology gaps specific to the field of biospecimen science and with relevance to cancer health disparities will also be discussed.
Currently available funding opportunity announcements are active with three receipt dates open through September, 2013. Enthusiasm from the NCI Board of Scientific Advisors and NCI leadership for the IMAT program indicates that these solicitations are likely to be active beyond these dates. Technology developers from all fields of research are encouraged to apply.
Citation Format: Anthony Dickherber. Innovative technology development to advance biospecimen science. [abstract]. In: Proceedings of the Fifth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2012 Oct 27-30; San Diego, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2012;21(10 Suppl):Abstract nr ED03-05.
Abstract A02: Targeted deep sequencing of second biopsy tissues from patients with acquired resistance (AR) to EGFR tyrosine kinase inhibitors harboring EGFR mutations: Preliminary results.
Authors: Ahn Myung-Ju , Kim Youngwook , Kim Kyoung-Mee , Choi Yoon-la , Han Joungho , Jho EunHye , Sun Joung-Mu , Ahn Jin-Sock , Park Keunchil 
Published: August 2014

Abstract
Background: Patients with EGFR activating mutation in non-small cell lung cancer (NSCLC) eventually develop AR to EGFR tyrosine kinase inhibitors (TKI) after durable and high response. Several mechanisms of AR to EGFR TKIs identified include T790M gatekeeper mutation, PIK3CA mutation, C-met amplification, transformation into small cell carcinoma or epithelial-mesenchymal transition (EMT). In the present study, to identify other genetic alterations, we performed targeted deep sequencing for over 700 hotspots in 50 cancer-related genes using next generation sequencing (NGS) technology.
Methods: Genomic DNA was extracted from FFPE tissue or pleural/pericardial fluid or primary culture cells of 57 NSCLC patients who developed AR to EGFR TKIs. Amplicons NGS libraries for 50 oncogenes included in Ion AmpliSeqTM Cancer Hotspot Panel v.2 were generated and sequenced in the Ion PGM Sequencer. Variant caller included in Torrent Suite Software was utilized to identify mutations in the samples, annotation was performed with IonTorrentTM Software.
Results: All 57 patients were treated with EGFR TKIs, gefitinib (n=39), erlotinib (n=17), or afatinib (n=1) as first-line or later line of therapy. 65% were female, 74% never smokers, median age of 58 years (range 25-77) and 98% were adenocarcinoma. 31 patients have exon 19 deletion and 14 with L858R at baseline. The median PFS for EGFR TKIs was 11 months (range 4-63). Targeted deep sequencing of second biopsy identified recurrent coexisting mutations of T790M in 52.6%. Other frequently altered genes include mutation of CTNNB1 (n=9), c-KIT (n=7), c-met (n=7), SMARCB1 (n=5), PDGFRA (n=5), PTEN (n=2), NRAS (n=2), and PIK3CA (n=1). However, in order to investigate whether these recurrent mutations observed in second biopsy represent genes associated with AR or pre-existing genes, targeted deep sequencing of available paired baseline samples will be performed and updated.
Conclusions: We found that NGS technology is feasible in FFPE tissues. Although T790M mutation confers the most common resistant mechanism to EGFR TKI, several detected genetic mutations are novel observations which might provide potential candidates for AR mechanisms. Further validation results will be discussed.
Citation Format: Myung-Ju Ahn, Youngwook Kim, Kyoung-Mee Kim, Yoon-la Choi, Joungho Han, EunHye Jho, Joung-Mu Sun, Jin-Sock Ahn, Keunchil Park. Targeted deep sequencing of second biopsy tissues from patients with acquired resistance (AR) to EGFR tyrosine kinase inhibitors harboring EGFR mutations: Preliminary results. [abstract]. In: Proceedings of the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer; 2014 Jan 6-9; San Diego, CA. Philadelphia (PA): AACR; Clin Cancer Res 2014;20(2Suppl):Abstract nr A02.